These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2292455)

  • 1. THF-gamma 2, a synthetic thymic hormone, increases effectiveness of combined chemotherapy and immunotherapy against RPC-5 murine plasmacytoma.
    Ophir R; Pecht M; Relyveld EH; Burstein Y; Ben-Efraim S; Trainin N
    Int J Immunopharmacol; 1990; 12(7):751-4. PubMed ID: 2292455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-gamma 2 in combination with an "immunomodulating" or a "non-immunomodulating" drug.
    Ophir R; Pecht M; Burstein Y; Harshemesh H; Ben-Efraim S; Trainin N
    Int J Cancer; 1991 Apr; 48(1):96-100. PubMed ID: 2019463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A synthetic thymic hormone, THF-gamma 2, repairs immunodeficiency of mice cured of plasmacytoma by melphalan.
    Ophir R; Pecht M; Rashid G; Halperin D; Lourie S; Burstein Y; Ben-Efraim S; Trainin N
    Int J Cancer; 1990 Jun; 45(6):1190-4. PubMed ID: 2141006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of murine Lewis lung carcinoma metastases by combined chemotherapy and intranasal THF-gamma 2 immunotherapy.
    Rashid G; Ophir R; Pecht M; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y; Keisari Y
    J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):324-33. PubMed ID: 8941872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy.
    Ophir R; Pecht M; Keisari Y; Rashid G; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y
    Immunopharmacol Immunotoxicol; 1996 May; 18(2):209-36. PubMed ID: 8771368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of protective antitumor immune response against a murine plasmacytoma not curable by alkylating-drug treatment.
    Ophir R; Jackman A; Relyveld EH; Ben-Efraim S
    Anticancer Res; 1990; 10(1):231-5. PubMed ID: 2334133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymic humoral factor, THF-gamma 2, enhances immunotherapy of murine cytomegalovirus (MCMV) infection by both CD4+ and CD8+ immune T cells.
    Rager-Zisman B; Segev Y; Blagerman S; Palmon A; Tel-Or S; Pecht M; Trainin N; Burstein Y
    Immunol Lett; 1993 Dec; 39(1):23-31. PubMed ID: 7908278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. THF-gamma 2, a thymic hormone, increases immunocompetence and survival in 5-fluorouracil-treated mice bearing MOPC-315 plasmacytoma.
    Ophir R; Pecht M; Halperin D; Rashid G; Burstein Y; Ben-Efraim S; Trainin N
    Cancer Immunol Immunother; 1989; 30(2):119-25. PubMed ID: 2598178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
    Adler A; Keisari Y; Ofir R
    J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Mokyr MB
    Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
    Bocian RC; Ben-Efraim S; Dray S; Mokyr MB
    Cancer Immunol Immunother; 1984; 18(1):41-8. PubMed ID: 6435857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of myeloid colony-formation in bone marrow of intact and neonatally thymectomized mice by the thymic hormone THF-gamma 2.
    Pecht M; Lourie S; Burstein Y; Zipori D; Trainin N
    Exp Hematol; 1993 Feb; 21(2):277-82. PubMed ID: 8425564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of a fatal murine cytomegalovirus infection with thymic humoral factor (THF-gamma 2) treated immune spleen cells.
    Rager-Zisman B; Zuckerman F; Benharroch D; Pecht M; Burstein Y; Trainin N
    Clin Exp Immunol; 1990 Feb; 79(2):246-52. PubMed ID: 2155728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
    Mokyr MB; Bartik MM; Ahn MC
    Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.
    Mokyr MB; Kalinichenko T; Gorelik L; Bluestone JA
    Cancer Res; 1998 Dec; 58(23):5301-4. PubMed ID: 9850053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors.
    Laude M; Russo KL; Mokyr MB; Dray S
    Cancer Immunol Immunother; 1993 Jul; 37(2):89-96. PubMed ID: 8319246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.
    Satoh K; Kan N; Okino T; Nakanishi M; Mise K; Teramura Y; Yamasaki S; Ohgaki K; Tobe T
    Cancer Immunol Immunother; 1991; 32(5):273-9. PubMed ID: 1998969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulation of antitumor response by chemotherapy.
    Ben-Efraim S
    Contrib Gynecol Obstet; 1985; 14():199-205. PubMed ID: 2933224
    [No Abstract]   [Full Text] [Related]  

  • 19. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E; Wise JA; Dray S; Mokyr MB
    Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.
    Wu Y; Deng Z; Wang H; Ma W; Zhou C; Zhang S
    BMC Immunol; 2016 Sep; 17(1):29. PubMed ID: 27645787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.